The estimated Net Worth of Robert M Plenge is at least $515 Tysiąc dollars as of 10 March 2024. Robert Plenge owns over 9,143 units of Telesis Bio Inc stock worth over $25,809 and over the last 6 years he sold TBIO stock worth over $44,754. In addition, he makes $444,226 as Independent Director at Telesis Bio Inc.
Robert has made over 3 trades of the Telesis Bio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 9,143 units of TBIO stock worth $15,543 on 10 March 2024.
The largest trade he's ever made was exercising 9,143 units of Telesis Bio Inc stock on 10 March 2024 worth over $15,543. On average, Robert trades about 1,311 units every 28 days since 2019. As of 10 March 2024 he still owns at least 15,182 units of Telesis Bio Inc stock.
You can see the complete history of Robert Plenge stock trades at the bottom of the page.
Dr. Robert Plenge M.D. Ph.D. serves as Independent Director of the Company. Dr. Plenge has served as a member of our board of directors since April 2019. Since November 2019, Dr. Plenge has served as senior vice president, research and early development at Bristol Myers Squibb, a pharmaceutical company. Previously, Dr. Plenge served as vice president, translational development, research and early development and head of the Inflammation and Immunology Thematic Center of Excellence Unit at Celgene Corporation, a biopharmaceutical company, since May 2017. Prior to joining Celgene, Dr. Plenge was vice president and head of translational medicine at Merck & Co., Inc., a pharmaceutical company, from July 2013 to May 2017. Prior to transitioning to the pharmaceutical industry, he was on the faculty of Harvard Medical School and an Associate Member of the Broad Institute while practicing clinical rheumatology and running a research laboratory at Brigham and Women’s Hospital from 2007 to 2013. Dr. Plenge completed his internal medicine residency as a molecular medicine fellow at University of California, San Francisco in 2002, served as rheumatology fellow at Brigham and Women’s Hospital from 2002 to 2006 and post-doctoral research fellow at the Broad Institute from 2003 to 2007. Dr. Plenge received a B.S. from the University of California, San Diego in 1992, and received his M.D. and Ph.D. degrees from Case Western Reserve University in 2000. Plenge is qualified to serve on our board of directors because of his experience assisting companies develop strategic vision, and implementation and partnerships of novel therapeutics, and because of his practice of medicine.
As the Independent Director of Telesis Bio Inc, the total compensation of Robert Plenge at Telesis Bio Inc is $444,226. There are 4 executives at Telesis Bio Inc getting paid more, with Ronald Renaud having the highest compensation of $3,386,150.
Robert Plenge is 49, he's been the Independent Director of Telesis Bio Inc since 2019. There are 9 older and 4 younger executives at Telesis Bio Inc. The oldest executive at Telesis Bio Inc is Jean-Francois Formela, 63, who is the Independent Director.
Robert's mailing address filed with the SEC is BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk oraz Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: